Prolomet XL

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prolomet XL

Quick Facts

Property Description
Active ingredient Metoprolol Succinate
Form Extended-Release Tablet (XL)
Pharmacological class beta1-Selective Adrenoceptor Inhibitor (Cardioselective Beta-blocker)
Common use (General) Continuous cardiovascular support and blood pressure management
Origin Synthetic (Chemically derived)

What Type of Medicine is Prolomet XL?

Prolomet XL is a synthetic, single-ingredient prescription drug that operates as a cardioselective beta-blocker, specifically developed to ensure stable heart function and systemic circulation. Its active compound, Metoprolol Succinate, places it within the beta-Adrenergic Receptor Blocking Agent class, which is clinically recognized for its efficacy in cardiovascular medicine. The medicine is intended for continuous, long-term systemic pressure management, which medical consensus confirms is vital for reducing the risk of major cardiovascular events.

The Role of Metoprolol Succinate and the XL Formulation

The distinguishing feature of Prolomet XL is its extended-release tablet (XL) form, which facilitates once-daily administration via oral administration. The Metoprolol Succinate salt form is engineered for this long-acting, controlled-release profile, a key differentiator from the immediate-release Metoprolol Tartrate versions. This formulation uses a specialized multiple unit system to guarantee a gradual release of the active ingredient over twenty-four hours. This design ensures that patients receive a consistent anti-adrenergic effect throughout the entire day, minimizing the fluctuations in drug levels that can occur with shorter-acting preparations.

General Purpose: Reducing the Workload on the Heart

The core purpose of Prolomet XL is to effectively reduce the workload on the heart and enhance its overall efficiency. As a beta1-selective inhibitor, the medication works by blocking specific receptor sites, which results in a deliberate slowing of the heart rate and a lessening of the force of the heart muscle’s contractions. This crucial cardio-selective action is vital for managing the heart’s oxygen demands. The continuous, steady activity provided by the XL form makes it a foundational component in long-term strategies aimed at promoting a more regular, stable rhythm and relieving chronic strain on the cardiovascular system.

Regulatory References

  1. DailyMed Label for Metoprolol Succinate ER

What side effects are possible with Prolomet XL?

Possible Side Effects and Safety Information

The safety profile of Prolomet XL (Metoprolol Succinate Extended-Release) is classified based on frequency and the physiological systems affected, as documented in official government regulatory information.

Frequency-Classified Adverse Reactions

Adverse reactions are organized into categories reflecting their observed incidence rates in clinical studies:

  • Very Common (affecting ge 1 in 10 persons): Fatigue.
  • Common (affecting ge 1 in 100 to < 1 in 10 persons): Bradycardia (slow heart rate), dizziness, headache, nausea, abdominal pain, diarrhea, constipation, and shortness of breath upon exertion.
  • Uncommon: Depression, sleep disturbances (including nightmares), cold extremities, rash, and swelling (edema).

Serious Adverse Reactions and Safety Constraints

Regulatory documents list specific safety concerns that require attention. Serious reactions documented include the worsening of heart failure—a risk noted particularly at the start of therapy or during dose increases. Severe bradycardia and second- or third-degree heart block are also listed as serious adverse reactions.

The medication is strictly contraindicated in individuals with specific pre-existing heart conditions, such as cardiogenic shock or decompensated heart failure. A key safety constraint is the documented risk associated with abrupt cessation of therapy; sudden withdrawal, especially in patients with existing ischemic heart disease, is associated with the exacerbation of angina or the possibility of a myocardial infarction.

Overdose and Emergency Response

Overdose involving metoprolol succinate, the active ingredient in Prolomet XL, can lead to severe and potentially life-threatening clinical manifestations that necessitate mandated emergency action. Officially documented signs typically reflect an exaggerated cardiovascular effect, including the rapid onset of severe bradycardia (excessively slow heart rate), profound hypotension (dangerously low blood pressure), and atrioventricular block. Serious outcomes listed in regulatory documents include the progression to acute cardiac insufficiency and cardiogenic shock, and in the most severe cases, asystole or cardiac arrest.

For any suspected overdose, regulatory guidance uniformly requires the patient to seek immediate medical attention, and emergency services must be contacted immediately. Hospital monitoring, often within an intensive care setting, may be necessary due to the severe nature of the expected clinical profile. The overdose picture may also include signs of respiratory distress like bronchospasm and hypoxia, and central nervous system effects such as impaired consciousness or coma. Treatment focuses on providing symptomatic and supportive measures, involving specific pharmacological interventions such as atropine, glucagon, and vasopressors to manage the physiological derangements, since hemodialysis is noted as being unlikely to contribute usefully to drug elimination.

Therapeutic Uses of Prolomet XL

Quick Facts: Prolomet XL Therapeutic Uses

  • High Blood Pressure (Hypertension)
  • Chest Pain (Angina Pectoris)
  • Heart Failure (Symptomatic chronic mild to severe)
  • Heart Rhythm Disorders (Cardiac Arrhythmias, especially supraventricular tachycardia)
  • Migraine Prophylaxis (Prevention of migraine headaches)

Prolomet XL is a prescription medicine used to manage several cardiovascular conditions. Its extended-release formulation provides controlled and predictable delivery of its active ingredient, metoprolol succinate, for once-daily dosing, helping to maintain a steady therapeutic effect.

The drug is medically prescribed for the treatment of high blood pressure (hypertension), which helps to reduce the risk of critical cardiovascular events such as stroke and myocardial infarction (heart attack). It is also indicated for the long-term management of angina pectoris, or chest discomfort due to reduced blood flow to the heart muscle, by lowering the heart's oxygen demand.

Furthermore, Prolomet XL is utilized as an adjunct to standard therapy for symptomatic chronic mild to severe heart failure to improve patient survival and clinical status. It is also used to manage certain cardiac arrhythmias and for the prevention of migraine headaches.

Eligibility and Restrictions for Use

Who Can and Cannot Use Prolomet XL?

Eligibility for Prolomet XL (Metoprolol Succinate Extended-Release) is strictly defined by regulatory criteria, primarily based on a patient's cardiac status, age, and organ function. The medication is contraindicated and must not be used by patients with severe bradycardia, cardiogenic shock, or high-grade heart blocks (second- or third-degree), or those with sick sinus syndrome unless a permanent pacemaker is in place. Use is also prohibited in cases of decompensated heart failure requiring intravenous inotrope therapy.


Restrictions and Limitations by Population

Population Category Regulatory Status Key Restriction
Pediatric Use Limited/Not Established Not recommended for children under 6 years of age. Use is established only for hypertension in children 6 years old.
Severe Hepatic Impairment Restricted Use Requires lower initial dosing due to increased blood drug levels.
Bronchospastic Diseases Caution/Restriction Should generally be avoided; if necessary, use the lowest effective dose.
Pregnancy/Lactation Restricted Use Use only if the potential benefit justifies the potential fetal or infant risk; the drug is excreted into breast milk.
Renal Impairment Established Use No specific dose adjustment is typically required.

Eligibility is also affected by metabolic conditions; for example, the drug must be used with caution in patients with diabetes mellitus as it may mask the signs of hypoglycemia.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Prolomet XL (Metoprolol Succinate Extended-Release) is structured around documented pharmacokinetic and pharmacodynamic patterns, as detailed in regulatory documents.

Pharmacokinetic Interactions

Metoprolol is primarily metabolized by the CYP2D6 enzyme. Co-administration with strong CYP2D6 inhibitors is officially documented to increase the plasma concentration of metoprolol, which may reduce its beta1-selectivity. This effect is particularly relevant in individuals classified as CYP2D6 poor metabolizers, who inherently have marked increases in metoprolol blood levels due to reduced clearance.

Pharmacodynamic Interactions

Co-administration with other medicines that slow heart rate or atrioventricular (AV) conduction can result in additive effects.

  • Non-dihydropyridine Calcium Channel Blockers (e.g., Verapamil, Diltiazem) and Digitalis glycosides have been shown to increase the risk of severe bradycardia and AV conduction delay.
  • Catecholamine-depleting drugs (e.g., Reserpine) may lead to additive effects, resulting in profound hypotension or marked bradycardia.
  • Co-administration with Clonidine requires a specific procedural restriction: if therapy is to be discontinued, the beta-blocker must be stopped first, before the gradual withdrawal of Clonidine, to manage the risk of rebound hypertension.

Interaction with Food and Alcohol

Interaction documentation notes that the bioavailability of the extended-release tablet formulation is not significantly affected by food. However, some regulatory labels for metoprolol succinate extended-release capsules caution that alcohol may interfere with the controlled-release properties, resulting in a rapid release of the medicine.

Mechanism of Action

Prolomet XL (metoprolol succinate) acts as a selective antagonist primarily targeting the beta1-adrenoceptors, which are highly concentrated in myocardial tissue. This mechanism blocks the binding of catecholamines (like noradrenaline and adrenaline) to these receptors, which results in the modulation of sympathetic nervous system (SNS) influence on cardiac activity.

By inhibiting beta1 activation, the drug modifies the subsequent intracellular signaling cascade, specifically reducing the formation of cyclic AMP (cAMP) and limiting the phosphorylation of key proteins. This modification in the signal transduction pathway contributes to a reduced rate of electrical impulse generation and transmission (negative chronotropy).

The direct mechanistic consequence of the reduced heart rate and decreased contractility (negative inotropy) contributes to a reduction in the major determinants of myocardial oxygen consumption (rate, contractility, and wall tension). This mechanism reduces the energy requirements of the myocardium, altering the balance between myocardial oxygen supply and demand.

Dosage and Administration Information

How Prolomet XL is Used: Official Administration Guidelines

Prolomet XL, a brand of metoprolol succinate extended-release tablets, is intended for long-term use and must be administered strictly according to established instructions to ensure its controlled-release function. The official protocol emphasizes once-daily oral administration at the same time each day.

Dosage and Scheduling

Indication Initial Adult Dosing Maximum Recommended Daily Dose
Hypertension & Angina 25 mg to 100 mg once daily 400 mg once daily
Heart Failure 12.5 mg or 25 mg once daily 200 mg once daily

For most conditions, the dosage is adjusted, or titrated, at weekly or longer intervals until the optimal response is achieved. For heart failure, the dose is typically doubled every two weeks up to the maximum tolerated dose. Pediatric patients (ge 6 years) are started on a dose based on body weight, beginning at 1 mg/kg once daily, not to exceed 50 mg initially.

Administration Requirements

Instruction Detail
Route of Administration Oral (Swallowing the tablet)
Food Relationship May be taken with or without food
Tablet Handling Tablets are scored and may be divided, but the whole or half tablet must be swallowed whole and not crushed or chewed.
Discontinuation If treatment must be stopped, the dosage should be gradually reduced over a period of 1 to 2 weeks.

No dose adjustment is typically required for patients with renal impairment; however, patients with severe hepatic impairment should be monitored closely.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Prolomet XL

This section describes the types of clinical studies conducted for metoprolol succinate extended-release (Prolomet XL) and what those studies examined, based on authoritative medical sources. This information provides context and does not constitute individual medical advice.


Evidence for use in High Blood Pressure (Hypertension)

Research has involved Randomized Controlled Trials (RCTs) designed to evaluate the medicine in conditions associated with systemic imbalance. Studies explored the primary outcome of changes measured in blood pressure metrics over a 24-hour interval in adults with essential hypertension. Findings describe patterns observed in blood pressure metrics and related physiological strain, such as Heart Rate. A key limitation is that follow-up durations were limited in some efficacy studies, meaning data for long-term outcomes like major cardiovascular events are often considered alongside broader evidence from metoprolol as a class.


Evidence for use in Heart Failure

The evidence base is rooted in large-scale, double-blind, placebo-controlled mortality trials (such as MERIT-HF). These studies explored the medicine's use in stable adults with chronic heart failure (NYHA Class II and III) already receiving standard therapies. Research explored patient outcomes over defined intervals, focusing on all-cause mortality and hospitalization rates. Findings describe observed patterns in these outcomes compared to the placebo group, with benefits noted across various subgroups, including older adults.


What Remains Unclear About the Research

While studies have established key evidence, the results apply only to the specific populations studied, and the applicability to individuals with more advanced disease (e.g., NYHA Class IV heart failure) remains insufficiently established due to exclusion from major trials. Furthermore, evidence for other uses, such as migraine prevention, is often derived from pooled analyses of various metoprolol formulations, meaning dedicated, long-term data for the extended-release formulation may be limited for those indications.

Key Studies & References

  1. Chronic heart failure in adults: diagnosis and management (NICE guideline NG106)

Frequently Asked Questions (FAQ)

Common questions about Prolomet XL (FAQ)


Q: Is Prolomet XL used to treat conditions other than high blood pressure and angina?

Official regulatory documents confirm that Prolomet XL is approved to treat Hypertension (high blood pressure) and Angina Pectoris (chest pain).

It is also officially approved for use in stable adults with Heart Failure.


Q: Are there any long-term side effects associated with taking Prolomet XL?

Official safety documents do not indicate that long-term use increases the overall risk of side effects compared to short-term use.

However, worsening heart failure is a serious adverse reaction that has been reported, requiring close monitoring during chronic treatment.


Q: Is dizziness or fatigue a temporary or ongoing side effect of Prolomet XL?

Dizziness and fatigue are listed as common adverse reactions. Official product information indicates that these effects are often temporary and may lessen as the body adjusts to the medicine.


Q: Are there specific foods or supplements that should be avoided while taking Prolomet XL?

Regulatory documents generally note that herbal remedies and dietary supplements are not typically tested for interactions with prescription medicines like metoprolol. For this reason, official information advises caution regarding the use of such products.


Q: Is there a concern about taking Prolomet XL with other blood pressure medicines?

Prolomet XL can be administered alongside other medicines for high blood pressure. However, combining it with certain agents that slow the heart rate may result in additive effects, such as a severely slow pulse, which requires close monitoring.


Q: Is Prolomet XL suitable for use in the elderly population?

Clinical research has explored patient outcomes in older adult subgroups, particularly in the treatment of heart failure. Official documents note that older individuals may clear the medicine more slowly, potentially increasing the risk of side effects like dizziness or fatigue.


Q: Can a patient with a history of depression use Prolomet XL?

Depression is listed as an uncommon adverse reaction. While a pre-existing history is not listed as a contraindication, official documents suggest that caution may be warranted for patients with a history of mood disorders.


Q: What does research indicate about the use of Prolomet XL for migraine prevention?

Research evidence for metoprolol as a class supports its use for migraine prevention. However, dedicated, long-term research specific to the extended-release formulation for this purpose may be limited.


Q: Is there a specific time of day Prolomet XL is recommended to be taken?

The official product information emphasizes that the medicine should be taken once daily at the same time each day to maintain consistent blood levels. The specific time of day (morning or evening) is generally not mandated for the extended-release formulation.


Q: What is the risk of fainting or dizziness when standing up (orthostatic hypotension) with this drug?

Official product information states that dizziness and lightheadedness are common side effects. Patients may experience lightheadedness when changing positions, and official information suggests rising slowly may reduce this risk.


Q: Does taking Prolomet XL make a person more likely to experience weight gain?

Weight gain has been reported as an adverse reaction with metoprolol. Unexplained weight gain is noted as a potential sign of worsening heart failure, which is a serious safety concern described in regulatory documents.


Q: Can Prolomet XL be taken at the same time as NSAID pain relievers (like ibuprofen)?

Regulatory documents indicate that Non-steroidal Anti-inflammatory Drugs (NSAIDs) may reduce the blood pressure-lowering effect of metoprolol. Additionally, NSAIDs can cause fluid retention or worsen pre-existing heart conditions.


Q: What is the official information regarding Prolomet XL causing sexual dysfunction or decreased libido?

Decreased sexual ability or performance has been reported rarely as an adverse reaction in post-marketing surveillance. This information comes from official safety documents.


Q: What should a person know about driving or operating machinery while taking Prolomet XL?

Official information advises avoiding driving or operating machinery until the individual knows how the medicine affects their alertness and coordination, as the medicine can cause dizziness, drowsiness, or fatigue.


Q: Is there any difference between Prolomet XL and Toprol-XL?

Prolomet XL and Toprol-XL are both brand names for the same medicine. They contain the active ingredient metoprolol succinate in the extended-release (XL) formulation.


Q: What happens if a person forgets to take a dose of Prolomet XL?

If a dose is missed, regulatory guidance states it should be taken as soon as it is remembered. If it is almost time for the next scheduled dose, the missed dose should be skipped entirely.

The dose should never be doubled to make up for a forgotten one.


Q: Are there any known interactions between Prolomet XL and herbal supplements?

Regulatory documents generally note that herbal remedies and dietary supplements are not typically tested for interactions with prescription medicines like metoprolol. For this reason, official information advises caution regarding the use of such products.


Q: Can Prolomet XL affect cholesterol levels?

Official clinical literature has noted that metoprolol, as a beta-blocker, may slightly raise triglyceride levels. It may also slightly lower HDL (often referred to as 'good') cholesterol levels.


Q: Is it possible for Prolomet XL to cause or worsen hair loss?

Official safety reports confirm that hair loss or thinning of the hair has been reported as a rare adverse reaction.


Q: Are there any documented interactions with over-the-counter cold and cough medicines?

Certain over-the-counter cold and cough medicines contain decongestant ingredients, such as pseudoephedrine. Regulatory documents note that these substances may raise blood pressure and potentially counteract the heart rate-slowing effects of metoprolol.


Q: Can Prolomet XL affect a person's reaction time or alertness?

Official information states the medicine can cause dizziness, drowsiness, or fatigue, which may affect a person's alertness and reaction time. Patients are advised to use caution when performing tasks that require mental alertness.

How should Prolomet XL be stored and disposed of?

Storage and Disposal of Prolomet XL

Official Storage Requirements

Prolomet XL (metoprolol succinate extended-release) must be stored at Controlled Room Temperature, which is between 20 C to 25 C (68 F to 77 F). The medicine must be kept away from excess heat and moisture and should remain in its original container, which must be kept tightly closed.

Child-Safety

It is mandatory to keep this medication out of the reach of children and pets and stored in a location that is up and away from sight and reach.

Disposal Instructions

Do not flush Prolomet XL down the toilet. The preferred method for discarding unused or expired tablets is a drug take-back program. If a take-back program is unavailable, the tablets should be mixed with an undesirable substance (such as dirt or coffee grounds) and sealed in a container before being thrown into the household trash, as specified by regulatory guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prolomet XL found in:

A-Z Index: